Biopharmaceutical Stocks

Potential short squeeze plays gained steam in 2021 and have continued to attract attention, with new traders looking for the next huge move. High short interest and a high cost to borrow are among the common traits that could lead to a short squeeze. Here’s a look at the top five short...

Potential short squeeze plays gained steam in 2021 and have continued through 2022 with new traders looking for the next huge move. High short interest and a high cost to borrow are among the common traits that could lead to a short squeeze. Here’s a look at the top five short squeeze...

Potential short squeeze plays gained steam in 2021 and has continued through 2022 with new traders looking for the next huge move. High short interest and a high cost to borrow are among the common traits that could lead to a short squeeze. Here’s a look at the top five short squeeze...

Potential short squeeze plays gained steam in 2021 and have continued through 2022 with new traders looking for the next huge move. Here’s a look at the top five short squeeze candidates for the week of Sept. 19, according to Fintel Data: NeuroBo Pharmaceuticals: Clinical stage biotechnology...

Potential short squeeze plays gained steam in 2021, with new retail traders looking for the next huge move. A short squeeze can occur when a heavily shorted stock rises in value instead of falling. Short sellers could be looking to close out their position and can face a loss if they have to buy...

Here is a look at some of the largest declining biotech names during the final week of 2016. Anthera Anthera Pharmaceuticals Inc (NASDAQ: ANTH) focuses on the development of products to treat serious diseases associated with inflammation, including enzyme replacement therapies and autoimmune...

Here is a summary of three biopharmaceutical stocks investors should keep on their radar for the remainder of the week, according to Bio Pharma Catalyst. Of particular note to investors, the data presented here best represents investor expectations and data derived from company presentations and...

Ophthotech Corp (NASDAQ: OPHT), a biopharmaceutical company that develops therapeutics for the treatment of eye diseases, saw its shares fall more than 13 percent Friday. The decline is attributed to an announcement by Regeneron Pharmaceuticals Inc (NASDAQ: REGN), a larger biopharmaceutical...

Shares of Galectin Therapeutics Inc (NASDAQ: GALT), a clinical-stage biopharmaceutical company that creates therapies for fibrotic disease and cancer, tumbled nearly 50 percent on Wednesday after the company said that a Phase 2a study called NASH-FX involving its GR-MD-02 therapy failed its...

Shares of XenoPort, Inc. (NASDAQ: XNPT), a small-cap bio-pharmaceutical company that focuses on the commercializing HORIZANT in the United States for the treatment of adults with moderate to severe primary Restless Legs Syndrome, surged higher by nearly 60 percent early Monday morning. XenoPort...

Shares of Chiasma Inc (NASDAQ: CHMA) plunged more than 60 percent Monday morning after the company provided an update regarding its New Drug Application for Mycapssa capsules. Chiasma is a biopharmaceutical company that focuses on treating patients with rare and serious chronic diseases. Its...